Clinical and translational advances in ovarian cancer therapy
PA Konstantinopoulos, UA Matulonis - Nature Cancer, 2023 - nature.com
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
Advances in the clinical management of uveal melanoma
Melanomas arising in the uveal tract of the eye are a rare form of the disease with a biology
and clinical phenotype distinct from their more common cutaneous counterparts. Treatment …
and clinical phenotype distinct from their more common cutaneous counterparts. Treatment …
Targeting FAK in anticancer combination therapies
JC Dawson, A Serrels, DG Stupack… - Nature Reviews …, 2021 - nature.com
Focal adhesion kinase (FAK) is both a non-receptor tyrosine kinase and an adaptor protein
that primarily regulates adhesion signalling and cell migration, but FAK can also promote …
that primarily regulates adhesion signalling and cell migration, but FAK can also promote …
GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma
P Silva-Rodríguez, D Fernández-Díaz, M Bande… - Cancers, 2022 - mdpi.com
Simple Summary The development of uveal melanoma is a multifactorial and multi-step
process, in which specific and recurrent mutations arise early. Among the recurrently …
process, in which specific and recurrent mutations arise early. Among the recurrently …
Focal adhesion kinase: from biological functions to therapeutic strategies
X Tan, Y Yan, B Song, S Zhu, Q Mei, K Wu - Experimental Hematology & …, 2023 - Springer
Focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, is a vital
participant in primary cellular functions, such as proliferation, survival, migration, and …
participant in primary cellular functions, such as proliferation, survival, migration, and …
Gαs–Protein kinase a (PKA) pathway signalopathies: the emerging genetic landscape and therapeutic potential of human diseases driven by aberrant Gαs-PKA …
Many of the fundamental concepts of signal transduction and kinase activity are attributed to
the discovery and crystallization of cAMP-dependent protein kinase, or protein kinase A …
the discovery and crystallization of cAMP-dependent protein kinase, or protein kinase A …
CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
H Lei, Z Wang, D Jiang, F Liu, M Liu, X Lei… - Cell Death & …, 2021 - nature.com
Androgen receptor (AR) signaling inhibitors provide limited survival benefits to patients with
prostate cancer (PCa), and worse, few feasible genomic lesions restrict targeted treatment to …
prostate cancer (PCa), and worse, few feasible genomic lesions restrict targeted treatment to …
Genetic landscape and emerging therapies in uveal melanoma
RS Seedor, M Orloff, T Sato - Cancers, 2021 - mdpi.com
Simple Summary Uveal melanoma is the most common primary intraocular malignancy in
adults. Unfortunately, metastasis develops in up to 50% of cases and outcomes are poor for …
adults. Unfortunately, metastasis develops in up to 50% of cases and outcomes are poor for …
Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
JJ Park, A Stewart, M Irvine, B Pedersen, Z Ming… - Cancer Gene …, 2022 - nature.com
Uveal melanoma (UM) is a rare cancer arising from melanocytes in the uveal tract of the eye.
Despite effective primary treatment, there is no approved therapy for metastatic UM and …
Despite effective primary treatment, there is no approved therapy for metastatic UM and …
Melanoma plasticity: promoter of metastasis and resistance to therapy
F Huang, F Santinon, RE Flores González… - Frontiers in …, 2021 - frontiersin.org
Melanoma is the deadliest form of skin cancer. Although targeted therapies and
immunotherapies have revolutionized the treatment of metastatic melanoma, most patients …
immunotherapies have revolutionized the treatment of metastatic melanoma, most patients …